$EWTX

Edgewise Therapeutics (Nasdaq: EWTX) reported Q2 2026 results and said its EDG-7500 12-week Phase 2 CIRRUS-HCM trial showed positive top-line data in obstructive and nonobstructive HCM, with Phase 3 planned for Q4 2026. In July 2026, it completed selling sevasemten and its muscular dystrophy business to Servier for $1.55B upfront plus up to $1.1B milestones. Q2 cash was about $460.7M; net loss was $57.3M.

Edgewise Therapeutics, Inc. (EWTX) filed an SEC Form 8-K — Results of Operations and Financial Condition. EX-99.1 2 tm2621653d1_ex99-1.htm EXHIBIT 99.1 Exhibit 99.1 News Release Edgewise Therapeutics Reports Second Quarter 2026 Financial Results – Announced positive top-line data from 12-week Phase 2 CIRRUS-HCM trial with EDG-7500 in obstructive and nonobstructive hypertrophic cardio

Edgewise Therapeutics Inc. (Nasdaq: EWTX) said it has closed the sale of its muscular-dystrophy business to France’s Les Laboratoires Servier. The transaction includes a drug pipeline led by sevasemten and could be worth up to $2.65 billion, according to the company.

Servier completed its acquisition of Edgewise Therapeutics’ muscular dystrophy business for up to $2.65 billion, including $1.55 billion upfront and up to $1.1 billion in regulatory and commercial milestones, after regulatory clearance. The deal adds sevasemten, in a pivotal Becker muscular dystrophy cohort and Phase 2 Duchenne study. (EWTX)

Edgewise Therapeutics, Inc. (EWTX) filed an SEC Form 8-K — Completion of Acquisition or Disposition of Assets. false 0001710072 0001710072 2026-07-10 2026-07-10 iso4217:USD xbrli:shares iso4217:USD xbrli:shares UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of The Securities Exchange Act of 1934 Date of Repor

Investing.com reports US insider trades disclosed Thursday. Buys: JCTC ($25,871; 11,009 shares at $2.35), BGDE ($16.7M Series D at $1,000), HDSN (~764,202 shares for ~$4.48M), BOLD (~$268,880), and COLB ($22,477). Sells: CRWV CEO sold ~$37.7M; EWTX CSO sold ~$7.88M; ALAB director sold ~$5.62M.

Russell Alan J (Chief Scientific Officer) sold 200,000 shares of Edgewise Therapeutics, Inc. (EWTX) at an average of $39.41 ($39.41–$39.41, $7.88M total) across 2 trades on 2026-07-01 under a Rule 10b5-1 trading plan.

HC Wainwright reaffirmed a “buy” rating on Edgewise Therapeutics (NASDAQ:EWTX) in a Tuesday report, setting a $45.00 price target (about 32.3% above the prior close). The stock fell to $34.02 on Tuesday. The company reported Q1 EPS of -$0.46 versus -$0.50 consensus, and analysts forecast -2.01 EPS for the fiscal year.

US stock futures were flat after a three-day rally as investors looked ahead to this week’s FOMC meeting, Kevin Warsh’s first. S&P 500 and Nasdaq futures were up 0.1% and 0.3% at 8:00am ET. SpaceX shares rose in premarket, and the company agreed to buy Cursor in a $60 billion deal. Mag 7 stocks were mixed; TSLA and Nvidia were down.

Edgewise Therapeutics, Inc. (EWTX) filed an SEC Form 8-K — Submission of Matters to a Vote of Security Holders. false 0001710072 0001710072 2026-06-04 2026-06-04 iso4217:USD xbrli:shares iso4217:USD xbrli:shares UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of The Securities Exchange Act of 1934 Date of Repor